Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Up 1.2 %

Shares of Brainstorm Cell Therapeutics stock opened at $0.24 on Monday. The firm’s 50 day simple moving average is $0.31 and its two-hundred day simple moving average is $0.42. The firm has a market capitalization of $17.02 million, a price-to-earnings ratio of -0.76 and a beta of 0.35. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $1.03.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). During the same period in the previous year, the business posted ($0.27) earnings per share. On average, sell-side analysts predict that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities & Exchange Commission. 14.33% of the stock is owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.